GlassScriptPhysician profile
Amy J Jackson
NPI 1972866085
$1,723.53
in general payments reported to CMS, 2019-2025
26 companies · $792 in 2025
The $792 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $87.25 · 2023: $290 · 2024: $555 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,636.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $344.25 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Supernus Pharmaceuticals, INC. | $245.57 | 2024-2025 | Qelbree |
| Luye Pharma (USA) LTD. | $138.90 | 2025 | Erzofri Extended-Release |
| Novo Nordisk INC | $118.62 | 2022-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $84.41 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $75.97 | 2024-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $72.81 | 2024-2025 | Uzedy, Austedo Xr |
| Medtronic, INC. | $69.95 | 2023-2024 | Minimed 780g, Intellis Adaptivestim |
| Glaxosmithkline, LLC. | $65.33 | 2023 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $63.57 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $47.62 | 2024-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $45.36 | 2023-2025 | Gattex, Trintellix |
| Novartis Pharmaceuticals Corporation | $40.96 | 2024-2025 | |
| Amgen INC. | $36.09 | 2024-2025 | Otezla, Repatha, Repatha |
| Axsome Therapeutics, INC. | $35.89 | 2024 | Auvelity |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $35.83 | 2023-2024 | Spravato, Xarelto |
| Lundbeck LLC | $34.35 | 2022-2024 | Rexulti |
| Acadia Pharmaceuticals INC | $27.26 | 2023 | Nuplazid |
| Indivior INC. | $23.58 | 2024 | Sublocade |
| Neos Therapeutics, LP | $22.13 | 2025 | Adzenys Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $19.63 | 2024 | |
| Corium, LLC | $17.13 | 2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.74 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $14.75 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Amneal Pharmaceuticals LLC | $14.72 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.